TCF7L2 promotes beta cell regeneration in human and mouse pancreas
- First Online:
- Cite this article as:
- Shu, L., Zien, K., Gutjahr, G. et al. Diabetologia (2012) 55: 3296. doi:10.1007/s00125-012-2693-z
- 1.5k Downloads
Diabetes is characterised by loss and dysfunction of the beta cell. A major goal of diabetes therapy is to promote the formation of new beta cells. Polymorphisms of T cell factor 7-like 2 (TCF7L2) are associated with type 2 diabetes, negatively regulating beta cell survival and function. Here, we provide evidence for a role of TCF7L2 in beta cell proliferation and regeneration.
Pancreatic sections from three mouse models (high-fat diet, exendin-4 and streptozotocin-treated mice) and from healthy individuals and patients with type 2 diabetes were used to investigate the association of beta cell regeneration and TCF7L2 levels. To analyse a direct effect of TCF7L2 on duct cell to beta cell conversion, TCF7L2 was overexpressed in isolated exocrine cells.
TCF7L2 levels correlated with beta cell compensation during high-fat diet feeding. TCF7L2 was increased together with pancreatic duct cell proliferation and differentiation. Small islet-like cell clusters (ICCs) that contained TCF7L2 originated in the vicinity of the ductal epithelium. In human isolated exocrine tissue, TCF7L2 overexpression induced proliferation of pancreatic duct cells and ICC formation next to duct cells, an effect dependent on the JAK2/STAT3 pathway.
The present study demonstrates that TCF7L2 overexpression fosters beta cell regeneration. Our findings imply correlation of TCF7L2 levels and new beta cell formation.
KeywordsBeta cell regeneration Diabetes Islets TCF7L2
Green fluorescent protein
Gastric inhibitory polypeptide
Islet-like cell cluster
Janus kinase 2
Pancreatic and duodenal homeobox 1
Phosphorylated signal transducer and activator of transcription 3
Small interfering RNA
Signal transducer and activator of transcription 3
T cell factor
T cell factor 7-like 2
Worldwide studies have reported a strong linkage of single nucleotide polymorphisms in the TCF7L2 gene with type 2 diabetes . T cell factor 7-like 2 (TCF7L2) is a transcription factor and major effector of Wnt signalling that is found in several tissues, including the gut and pancreas. Wnt signalling is essential for cell development and regeneration. In pancreatic beta cells, it fosters beta cell proliferation, insulin secretion , neonatal growth and regeneration .
TCF7L2 itself promotes beta cell proliferation, protects against apoptosis and improves insulin secretion [4, 5, 6]. TCF7L2 knockout islets show impaired glucose-, glucagon-like peptide-1 (GLP1)- and gastric inhibitory polypeptide (GIP, also known as glucose-dependent insulinotropic peptide)-stimulated insulin secretion . In addition, beta cell-specific Tcf7l2 knockout mice display impaired glucose tolerance .
As one important mechanism of the deleterious effect of TCF7L2 loss in the beta cell, we have previously detected the parallel downregulation of beta cell GIP and GLP receptors , which may explain the limited incretin response in patients with the TCF7L2 risk alleles . The two incretin hormones GLP1 and GIP are important targets for diabetes therapy because of their ability to potentiate glucose-stimulated insulin secretion, as well as to promote beta cell proliferation, beta cell neogenesis and survival in animal models .
In line with these studies, in rats with TCF7L2 knockdown by specific Tcf7l2 morpholino-oligonucleotides, the process of beta cell regeneration was significantly inhibited . GLP1 and TCF7L2 share common pathways and both promote beta cell survival. In the current study, we investigated whether TCF7L2 itself can promote beta cell regeneration and neogenesis.
Three mouse models of beta cell renewal and regeneration, including high-fat diet (HFD)/high-sucrose diet, exendin-4 and streptozotocin (STZ)-treated mice [10, 11, 12], were investigated to evaluate the effects of TCF7L2 on new beta cell formation. We aimed to clarify how TCF7L2 levels change during the compensatory adaptation of beta cell mass during HFD feeding and later during diabetes progression. Using the HFD mouse model, which shows progression from metabolically healthy obesity to impaired glucose tolerance and severe diabetes, enabled us to directly correlate TCF7L2 production with glycaemia and diabetes.
C57BL/6J mice (Jackson Laboratories, Bar Harbor, ME, USA) aged 6 weeks or 14 months were fed an HFD/high-sucrose diet (‘Surwit’ Research Diets, New Brunswick, NJ, USA)  or normal diet (ND; Harlan Teklad Rodent Diet 8604) for 4–16 weeks. Exendin-4 (10 nmol/kg; Sigma) or PBS was injected i.p. daily for 7 days, or a single dose of 90 mg/kg freshly prepared STZ in citrate buffer (pH 4.5) or citrate buffer was used as a control. All animals were housed in a temperature-controlled room with a 12 h light/dark cycle and were allowed free access to food and water in agreement with National Institutes of Health animal care guidelines §8 of the German animal protection law.
Isolated mouse and human pancreatic exocrine cells from islet isolations  were cultured on extracellular matrix-coated dishes (Novamed, Jerusalem, Israel) in DMEM supplemented with 10% FCS and penicillin–streptomycin (1%), with or without exposure to the Janus kinase 2 (JAK2) inhibitor AG490 (20 mmol/l; Sigma, St Louis, MO, USA). Human islets were isolated from the pancreases of five healthy organ donors at the University of Illinois at Chicago (IL, USA) and from Inserm/Université de Lille, Thérapie Cellulaire du Diabète (France) and cultured as previously described .
TCF7L2 plasmid and siRNA transfection
Isolated islets or exocrine cells were exposed to transfection Ca2+- Krebs Ringer’s/HEPES medium. After 1 h incubation, lipoplexes (Lipofectamine 2000; Invitrogen, Carlsbad, CA, USA)/DNA ratio 2.5:1, 3 μg DNA of TCF7L2 plasmid (full-length TCF7L2 from the Full-Length Mammalian Gene Collection, Invitrogen), or a pCMV–green fluorescent protein (GFP) control plasmid or 50 nM small interfering RNA (siRNA) to TCF7L2 (RNAs of 21 nucleotides, designed to target human TCF7L2; Stealth Select RNAi, Invitrogen) and scramble siRNA (Dharmacon, Lafayette, CO, USA) were added to transfect the cells as previously described [15, 16].
Pancreatic tissue and cultured mouse islets and isolated human pancreatic exocrine cells were processed as previously described . For details of antibodies and staining, see the electronic supplementary material (ESM). The University of Bremen ethics committee approved all studies involving human cells and organ donors.
Analysis of beta cell mass
Beta cell mass was measured as previously described . In brief, ten sections (spanning the width of the pancreas, which was cut along the head–tail axis) from each pancreas were stained with anti-mouse insulin antibody (Dako, Hamburg, Germany) and scanned with a Nikon MEA53200 (Nikon, Dusseldorf, Germany) microscope. The cross-sectional areas of pancreas and beta cells were determined by NIS-Elements software (Nikon). Beta cell mass/pancreas was estimated by the product of the relative cross-sectional area of beta cells per total tissue and the weight of the pancreas.
RNA extraction and RT-PCR
Total RNA was isolated from cultured human pancreatic exocrine cells as previously described . For quantitative analysis, we used the Applied Biosystems StepOne Real-Time PCR system (Applied Biosystems, Carlsbad, CA, USA) with a commercial kit (Power SYBR Green PCR Master Mix; Applied Biosystems). For signal transducer and activator of transcription 3 (STAT3) analysis, TaqMan gene expression assays (Fast Universal PCR Master Mix; Applied Biosystems) were used. The primers are described in the ESM.
Western blot analysis
Isolated cultured pancreatic exocrine cells were washed in PBS and lysed. Polyvinylidene fluoride filters were incubated with rabbit anti-TCF7L2 (clone C9B9, #2565), rabbit anti-STAT3 (#9132), rabbit anti-phosphorylated (p)-STAT3 (Tyr705, #9131), rabbit anti-actin (#4967) and rabbit anti-p-AKT (Serine473, #9271) (all Cell Signaling, Danvers, MA, USA), followed by incubation with horseradish-peroxidase-linked IgG peroxidase. Band density was analysed using DocIT LS image acquisition 6.6a (UVP BioImaging Systems, Upland, CA, USA).
Samples were evaluated in a randomised manner by a single investigator (L.S.) who was blinded to the treatment conditions. Data are presented as means ± SE. Mean differences were tested by Student’s t test. Bonferroni correction was used to account for multiplicity in the treated cells in vitro and mice in vivo. Because of the skew of the data, nonparametric methods were also applied to all TCF7L2 expression analyses. Robust median regression models were used to describe TCF7L2 expression, and the significance of differences was assessed with the Mann–Whitney U test. Immunostainings were analysed by resampling tests that consider all combinations of the possible permutations within each donor. Comparisons between GFP, GLP1 and TCF overproduction groups were performed by Kruskal–Wallis tests; multiple-adjustment p values were calculated by the closed testing principle.
TCF7L2 levels increase with adaptive beta cell compensation and are lost with diabetes progression
TCF7L2 levels decrease during diabetes progression at an older age
Beta cell replication and increased TCF7L2 levels in STZ and exendin-4 injected mice
Since TCF7L2 levels correlated with the compensation capacity in HFD-fed mice, we investigated whether this increase also occurs in mouse models of beta cell regeneration. Two standard regeneration models were used: (1) a single injection of STZ (90 mg/kg body weight); and (2) daily injections of exendin-4 (10 nmol/kg) for 1 week . Exendin-4 stimulates both beta cell replication and neogenesis , and a single dose of the beta cell toxin STZ in mice leads to 50% loss of beta cells, together with an increase in beta cell proliferation and regeneration at 7 days after the STZ injection .
Both STZ and exendin-4 injection led to increased beta cell proliferation (3.5- and 3.8-fold induction of beta cell proliferation, respectively, compared with vehicle control, p < 0.05; Fig. 3f, h, i). This was accompanied by increased intra-islet TCF7L2 levels both in STZ- and exendin-4-treated mice (two- and 1.8-fold more TCF7L2-positive beta cells in STZ- and exendin-4-treated mice, respectively, compared with vehicle-treated control mice, p < 0.05; Fig. 3g, j, k).
Increased TCF7L2 is associated with ductal epithelial cell proliferation and differentiation in STZ- and exendin-4-treated mice
Since we saw an association of TCF7L2 with beta cell proliferation in the pancreas, we next investigated whether there is beta cell neogenesis from ductal cells in STZ- and exendin-4-treated mice and whether this is paralleled by changes in TCF7L2 production.
The presence of pancreatic and duodenal homeobox 1 (PDX1)-positive cells in the pancreatic ductal epithelium has been demonstrated in rodent models following partial pancreatectomy , serving as a marker for new beta cell formation. We quantified PDX1/CK19 double-positive ductal cells by immunofluorescent staining in pancreatic sections from STZ- and exendin-4-treated mice (Fig. 4b). This revealed a significantly enhanced number of PDX1-positive ductal cells in STZ- and exendin-4-treated mice, while ductal PDX1 was almost absent in control mice (8.3- and 7.2-fold more PDX1/CK19 double-positive cells in STZ- and exendin-4-treated mice, respectively, compared with control mice, p < 0.005; Fig. 4b).
Newly formed beta cells from ductal cells should express beta cell and ductal cell markers at a certain stage. Also, small islet-like cell clusters (ICCs) have been reported to originate in the vicinity of the ductal epithelium . As presented in Fig. 4c, we observed ICC structures next to ductal cells in both STZ- and exendin-4-treated mice. Quantification of the number of ICCs near the pancreatic ducts revealed five- and fourfold increased number of beta cells next to the duct in STZ- and exendin-4-treated mice, compared with control mice (p < 0.005; Fig. 4c); all of these cells were TCF7L2-positive (see Fig. 4c, middle panel, insert).
Together with the appearance of PDX1-positive ductal epithelial cells and ICCs in STZ- and exendin-4-treated mice, significant 2.1- and 1.7-fold upregulation of TCF7L2 in ductal epithelial cells was observed in STZ- and exendin-4-treated mice, respectively, compared with control mice (Fig. 4d; p < 0.05). These observations indicate increased TCF7L2 levels during new beta cell formation.
Increased TCF7L2 levels correlate with insulin-positive ductal epithelial cells in patients with type 2 diabetes
After we observed an association of TCF7L2 levels with ductal proliferation and beta cell formation in the ductal vicinity, we investigated whether such a correlation also exists in the human pancreas. Increased ductal proliferation in the pancreas in obesity and in patients with type 2 diabetes was reported recently .
Overexpression of TCF7L2 could trigger ductal epithelial cell to beta cell conversion in vitro
Despite the increased ductal TCF7L2 levels, an adaptation of beta cell mass to insulin demand fails to occur in patients with type 2 diabetes. Nevertheless, we tested the possibility of whether overexpression of TCF7L2 in vitro might trigger beta cell formation in human exocrine tissue.
The incretin hormone GLP1 and its analogue exendin-4 stimulate beta cell neogenesis . GLP1R is expressed in ductal cells , and we applied GLP1 as a positive control of beta cell neogenesis. The RT-PCR results displayed in Fig. 6e demonstrate that both GLP1 treatment and TCF7L2 overexpression increased Pdx1 and Ngn3 mRNA levels, as well as Glp1r and Tcf7l2 mRNA expression, which confirms previous data from human islets showing a link between GLP1 and TCF7L2 signals .
TCF7L2 stimulates ductal cell differentiation through the JAK2/STAT3 pathway
To quantify such changes and to confirm an effect of STAT3 on TCF7L2-induced beta-cell formation, we performed western blotting and RT-PCR with mouse exocrine pancreatic tissue. Islets were hand-picked and the remaining exocrine cells were exposed to AG490, a specific JAK2 inhibitor , to further clarify whether ductal epithelial cell differentiation induced by TCF7L2 overexpression is JAK2/STAT3 dependent. GLP1, which is known to induce STAT3 phosphorylation, was used as positive control. In mouse pancreatic exocrine tissue, GLP1 as well as TCF7L2 overproduction (see western blot in Fig. 7d) induced strong phosphorylation of STAT3 (Fig. 7b, c). Also, and in confirmation with a previous report , total STAT3 levels were increased. The JAK2 inhibitor AG490 was associated with a significant reduction in GLP1-and TCF7L2-induced STAT3 phosphorylation. Downstream activation of AKT, which is induced by GLP1 and TCF7L2 in islets [4, 6, 26] and linked to STAT3 signalling , was also blocked by the JAK2 inhibitor (Fig. 7d). While successful TCF7L2 overproduction could be confirmed by western blot analysis (upregulation of the major 58 kDa band), GLP1 also induced TCF7L2 levels, which was inhibited by JAK2 inhibition, suggestive of a positive feedback loop.
Since STAT3 activation was responsible for AKT activation in mouse pancreatic exocrine cells, we investigated whether Tcf7l2 overexpression and GLP1 treatment could both induce islet transcription factors in a STAT3-dependent manner. GLP1 treatment and Tcf7l2 overexpression increased Pdx1 and insulin mRNA expression in isolated mouse exocrine cells compared with control (Fig. 7e–g). Hepatocyte nuclear factor-6 (onecut-1), which controls pancreatic endocrine differentiation at the precursor stage and regulates Ngn3 expression in the pancreas , was also increased by GLP1 and TCF7L2. In contrast, inhibition of STAT3 activation by AG490 treatment resulted in a significant reduction of Pdx1, insulin and Hnf6 mRNA in the treated exocrine cells, indicating that beta cell gene expression is controlled by JAK2/STAT3. In confirmation of the exocrine tissue experiments, TCF7L2 overexpression also induced p-STAT3 and total STAT3 protein (Fig. 7h) and Stat3 mRNA (Fig. 7i) expression in human isolated islets, while depleting TCF7L2 by siRNA had no effect (Fig. 7h, i), neither in islets nor in exocrine tissue.
Loss of functional beta cells is the crucial event in the development of type 1 and 2 diabetes. Regeneration of beta cells is one promising approach to restore the deficit in beta cell mass in patients with diabetes, but has so far been difficult to achieve. Theoretically, new adult beta cells arise either through differentiation of endocrine stem or progenitor cells or by replication of existing beta cells [29, 30].
Pancreatic ductal epithelial cells, acinar cells, other endocrine cells (e.g. alpha or delta cells) and mesenchymal stromal cells from bone marrow have been identified as beta cell precursors . In contrast, lineage-tracing studies in mice show that only the beta cell itself serves as a beta cell source through self-duplication , although this was recently not confirmed  and is challenged by the fact that alpha cells [33, 34], acinar cells [35, 36] and ductal cells  are also sources for new beta cell formation, the last of which has been confirmed in the current study. Another source of beta cells is facultative progenitors in regenerating pancreatic ducts . Differences certainly exist between mice and humans. Therefore, we abandoned complex lineage-tracing approaches in mice in this study and rather compared the effects of TCF7L2 expression in mouse and human pancreatic cells.
We observed that TCF7L2 fosters pancreatic ductal epithelial cell proliferation and differentiation. Together with an induction of TCF7L2 expression, more proliferating ductal epithelial cells were found during beta cell regeneration. Small ICCs, which all produced TCF7L2, originated in the vicinity of the ductal epithelium. TCF7L2 in ductal cells was clearly induced in type 2 diabetes. In some ducts, almost all cells stained positive for TCF7L2. In line with previous data , we observed an induction of proliferation in these ductal cells in human type 2 diabetes.
The attempt of beta cell regeneration, as suggested by the presence of beta cells in the vicinity of ductal cells, together with TCF7L2 expression in human type 2 diabetes and in the diabetic STZ mouse model, seems to be insufficient to compensate for the high demand of new beta cells under diabetic conditions. Despite the increase in TCF7L2, an adaptation of beta cell mass to the insulin demand fails to occur in type 2 diabetes, as well as in our experimental conditions of beta cell destruction. In addition, in the animal models, where we found up to 70% TCF7L2-positive ductal cells, only 1% was insulin positive. Higher ductal TCF7L2 production was observed in diabetic pancreases, but, in contrast, islet TCF7L2 is barely detectable . Nevertheless, overexpression of TCF7L2 in vitro triggered new beta cell formation in human exocrine tissue. One could speculate that the increase of TCF7L2 achieved in vivo may not be enough to maintain a sufficient beta cell mass. In contrast, TCF7L2 levels achieved by plasmid overexpression are much higher than the physiological increase, which occurred in vivo, and such high TCF7L2 levels could trigger beta cell regeneration.
Insufficient adaptation in the beta cell in response to increased demand was also observed under the HFD/high-sucrose (‘Surwit’) diet. While mice showed increased beta cell mass under the HFD/high-sucrose diet at up to 8 weeks, longer exposure resulted in further metabolic deterioration together with insufficient mass adaptation. TCF7L2 levels remained high at conditions of beta cell mass compensation (see ), but suddenly decreased to levels lower than under ND treatment when the diet was given for 12 weeks or longer. Similar defects in beta cell adaptation occurred in older mice. While young mice could increase beta cell mass in response to diet, old mice completely failed to increase their beta cell mass and showed further impaired glucose tolerance as well as a reduction in Tcf7l2 expression. Again, the physiological TCF7L2 increase in vivo failed to trigger long-term beta cell compensation.
The signalling pathways that promote duct cell differentiation and beta cell neogenesis are not clearly understood. Growth factors such as epidermal growth factor in combination with gastrin , IGF, TGF-beta [22, 39] and the acinar cell product known as islet neogenesis-associated protein  foster beta cell growth. The activation of the JAK2/STAT3 pathway occurs during generation of beta cells . A functional TCF-binding element was detected in the STAT3 promoter, and TCF7L2 binds specifically to it ; in addition, STAT–Wnt interactions have been previously reported in other cells [24, 25]. Here, we show that STAT3 mediates the effect of TCF7L2 and GLP1 on pancreatic exocrine cells in vitro and shows common intracellular pathways of TCF7L2 and GLP1. STAT3 activation seems to be essential for the differentiation of exocrine cells into beta cells, since inhibition of STAT3 significantly decreased beta cell-specific markers at the transcript level.
TCF7L2 overexpression increased Stat3 mRNA. In contrast, downregulation of TCF7L2 by siRNA failed to affect STAT3; no effect was seen on p-STAT3, total STAT3 or mRNA levels. Since STAT3 is a direct target of the beta-catenin/TCF pathway, we would have expected STAT3 downregulation by TCF7L2 depletion. Using siRNAs, we did not achieve full TCF7L2 depletion; the remaining TCF7L2 could still have maintained STAT3 levels. On the other hand, it is possible that further stimulation of the Wnt pathway is necessary to enhance STAT3; thus, at basally low levels of both TCF7L2 and p-STAT3, no effect could be observed. The major downstream signal of Wnt is beta-catenin, which is translocated to the nucleus to switch on Wnt target genes. We have shown also that TCF7L2 upregulation activates beta-catenin and its target genes . In turn, activated beta-catenin enhances STAT3 expression . Thus, it is possible that the activation of the Wnt pathway is necessary for STAT3 activation, which is not manipulated by TCF7L2 downregulation. However, the key question—how TCF7L2 overexpression affects STAT3 phosphorylation—remains unanswered, it is very likely that this involves activation of another kinase or the inactivation of a phosphatase. Further investigations are necessary to explain this effect in detail. In addition, whether different TCF7L2 splice variants, which are present in various tissues including islets [15, 41, 42, 43, 44, 45], are also present in ductal cells and whether they have differential effects on ductal cell replication and the formation of beta cell clusters next to the duct is not known and also remains to be elucidated.
In conclusion, our findings imply a correlation of TCF7L2 expression and beta cell regeneration as well as proliferation. TCF7L2 could trigger differentiation from ductal epithelial cells into beta cells in vitro. Our data support TCF7L2 as a new target for diabetes treatment to promote new beta cell formation.
We thank J. Bergemann for excellent technical assistance and F. Paroni and A. Ardestani (all University of Bremen, Bremen, Germany) for the critical discussion of the paper.
This work was supported by the European Foundation for the Study of Diabetes, the Chinese Diabetes Society, Lilly Research Fellowship, the University of Bremen Postdoctoral Research Program, the Natural Science Foundation of China (Grant No. 81102488), the German Research Foundation (DFG, MA4172/1–1) and the European Research Council.
Human islets were provided through the JDRF award 31-2008-413 (ECIT Islet for Basic Research program) and through the Integrated Islet Distribution Program, administered by the Administrative Bioinformatics Coordinating Center (ABCC), and supported by National Center for Research Resources (NCRR), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), JDRF and the Chicago Diabetes Project. Human pancreatic sections were from the National Disease Research Interchange, supported by the National Institutes of Health.
Duality of interest
The authors declare that there is no duality of interest associated with the manuscript.
LS, KZ, GG and KM designed the study, and performed and analysed research. JKC, FP and JO contributed new reagents or analytical tools and interpreted the data. All authors contributed to the writing of the paper and have approved the final version.